Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN60090 in advanced solid tumours
NCT03894540Phase 1Terminated
- Sponsor
- Ipsen
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IPN60090 in solid tumor (4 arms), sponsored by Ipsen. Primary endpoints: Treatment Emergent Adverse Events up to 219 days, Dose-Limiting Toxicities and 1 more. Started Mar 2019; status: terminated.
02
Drugs
IPN60090
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03894540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894540.